High-density lipoprotein mimetics: promises and challenges

被引:27
|
作者
Sviridov, Dmitri [1 ]
Remaley, Alan T. [2 ]
机构
[1] Baker IDI Heart & Diabet Inst, Lab Lipoprot & Atherosclerosis, Melbourne, Vic 3004, Australia
[2] NHLBI, Lipoprot Sect, NIH, Bethesda, MD 20892 USA
基金
英国医学研究理事会;
关键词
apolipoproteins; atherosclerosis; cholesterolmetabolism; lipoprotein metabolism; peptides; APOLIPOPROTEIN-A-I; REVERSE CHOLESTEROL TRANSPORT; PEPTIDE; 4F; ANTIINFLAMMATORY PROPERTIES; CORONARY ATHEROSCLEROSIS; REDUCES ATHEROSCLEROSIS; AMPHIPATHIC PEPTIDES; PLASMA-CLEARANCE; LESION FORMATION; OXIDIZED LIPIDS;
D O I
10.1042/BJ20150832
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The concept of lipoprotein mimetics was developed and extensively tested in the last three decades. Most lipoprotein mimetics were designed to recreate one or several functions of high-density lipoprotein (HDL) in the context of cardiovascular disease; however, the application of this approach is much broader. Lipoprotein mimetics should not just be seen as a set of compounds aimed at replenishing a deficiency or dysfunctionality of individual elements of lipoprotein metabolism but rather as a designer concept with remarkable flexibility and numerous applications in medicine and biology. In the present review, we discuss the fundamental design principles used to create lipoprotein mimetics, mechanisms of their action, medical indications and efficacy in animal models and human studies.
引用
收藏
页码:249 / 259
页数:11
相关论文
共 50 条
  • [1] High-density lipoprotein mimetics: Focus on synthetic high-density lipoprotein
    Shah, Prediman K.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (11): : 62N - 67N
  • [2] High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases
    Ikenaga, Masahiro
    Higaki, Yasuki
    Saku, Keijiro
    Uehara, Yoshinari
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2016, 23 (04) : 385 - 394
  • [3] Apolipoprotein A-I mimetics and high-density lipoprotein function
    Gordon, Scott M.
    Davidson, William S.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2012, 19 (02) : 109 - 114
  • [4] Detecting the functional complexities between high-density lipoprotein mimetics
    Sei, Yoshitaka J.
    Ahn, Jungho
    Kim, Taeyoung
    Shin, Eunjung
    Santiago-Lopez, Angel J.
    Jang, Seung Soon
    Jeon, Noo Li
    Jang, Young C.
    Kim, YongTae
    BIOMATERIALS, 2018, 170 : 58 - 69
  • [5] High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities
    Santos-Gallego, Carlos G.
    Badimon, Juan Jose
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (04): : 305 - 308
  • [6] Advances in high-density lipoprotein physiology: surprises, overturns, and promises
    Constantinou, Caterina
    Karavia, Eleni A.
    Xepapadaki, Eva
    Petropoulou, Peristera-Ioanna
    Papakosta, Eugenia
    Karavyraki, Marilena
    Zvintzou, Evangelia
    Theodoropoulos, Vassilis
    Filou, Serafoula
    Hatziri, Aikaterini
    Kalogeropoulou, Christina
    Panayiotakopoulos, George
    Kypreos, Kyriakos E.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2016, 310 (01): : E1 - E14
  • [7] Statins, high-density lipoprotein, and the low-density lipoprotein/high-density lipoprotein ratio
    Silva, JM
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (05): : 593 - 594
  • [8] High-density lipoprotein is a nanoparticle, but not all nanoparticles are high-density lipoprotein
    Cormode, David P.
    Fisher, Edward A.
    Stroes, Erik S. G.
    Mulder, Willem J. M.
    Fayad, Zahi A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (38) : E3548 - E3548
  • [9] HIGH-DENSITY LIPOPROTEIN
    不详
    LANCET, 1981, 1 (8218): : 478 - 480
  • [10] HIGH-DENSITY LIPOPROTEIN
    SCHAEFER, EJ
    ARTERIOSCLEROSIS, 1983, 3 (06): : 629 - 629